Table S2 from Results of an Open-label, Phase 1a/b Study of Pembrolizumab plus Olaratumab in Patients with Unresectable, Locally Advanced or Metastatic Soft Tissue Sarcoma
Key Points
Key points are not available for this paper at this time.
Abstract
Table S2: Dose reduction, delay, and omission due to AE.
AI에게 질문
Like
Bookmark
Share
AI에게 질문
Like
Bookmark
Share
Table S2 from Results of an Open-label, Phase 1a/b Study of Pembrolizumab plus Olaratumab in Patients with Unresectable, Locally Advanced or Metastatic Soft Tissue Sarcoma | Synapse